Celyad - News

Corporate › Non-regulated January 07, 2019

Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS

Corporate › Non-regulated November 15, 2018

Celyad to Participate at Upcoming Healthcare Conferences

Corporate › Non-regulated October 04, 2018

Celyad to present CYAD-01 solid tumor clinical updates and pre-clinical pipeline data at the 2018 SITC Annual Meeting

Corporate › Non-regulated September 26, 2018

Celyad appoints Carri Duncan as Vice-President Corporate Development & Communications

Corporate › Non-regulated September 25, 2018

Celyad to Participate at Upcoming Healthcare Conferences

Corporate › Non-regulated September 05, 2018

Celyad Successfully Doses First Colorectal Cancer Patient with CYAD-01 Following Preconditioning Chemotherapy

Corporate › Non-regulated August 30, 2018

Celyad to participate at upcoming healthcare conferences in September

Corporate › Non-regulated June 19, 2018

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

Corporate › Non-regulated May 09, 2018

Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018

Corporate › Non-regulated April 27, 2018

Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient

Corporate › Non-regulated March 29, 2018

Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Corporate › Non-regulated February 13, 2018

Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for the Treatment of Blood Cancers